NATHAN LEVIN
Osteopathic Medicine in New York, NY

2013004, Feb 14, 2013

Apr 22, 2011

13/642364

Peter Kotanko - New York NY, US
Stephan Thijssen - New York NY, US
Len Usvyat - Philadelphia PA, US
Nathan W. Levin - New York NY, US

G06Q 50/22

705 2

Identifying a patient undergoing periodic hemodialysis treatments at increased risk of death by a logistic regression model includes selecting one or more clinical or biochemical parameter parameters associated with a probability of death of the patient while the patient is undergoing periodic hemodialysis treatments, and estimating the probability of death of the patient over a future time interval by a logistic regression model including model coefficients, the model coefficients determined by analyzing data from deceased patients that were previously undergoing periodic hemodialysis treatments, the analysis including a longitudinal analysis backwards in time on the one or more clinical or biochemical parameters of the deceased patients. The patient is identified as having an increased risk of death if the probability of death of the patient is greater than a predetermined threshold probability.

7945317, May 17, 2011

Sep 10, 2004

10/570368

Nathan W. Levin - New York NY, US
Fansan Zhu - Flushing NY, US

Renal Research Institute, LLC - New York NY

A61B 5/05, A61B 5/103, A61B 5/117

600547, 600587

Methods and apparatus for providing bioimpedance analysis are provided. In certain aspects, equivalent circuit frequency response models are provided which lead to improved correlations with MRI data. The frequency response models take account of body composition, including the fat component of a body segment. Data obtained by performing bioimpedance spectroscopy (BIS) and MRI on the calves of subjects illustrates the improved correlations achieved compared to single frequency analyses at 50 kilohertz and analyses performed using the conventional Cole-Cole model.

2013019, Aug 1, 2013

Oct 12, 2011

13/879220

Nathan W. Levin - New York NY, US
Fansan Zhu - Flushing NY, US

FRESENIUS MEDICAL CARE HOLDINGS, INC. - Waltham MA

A61B 5/053

600547

Methods and apparatus for predicting/estimating the dry weight of an individual, e.g., a patient undergoing dialysis treatment, are provided. The techniques employ a bioimpedance measurement () on the individual's calf () to obtain information regarding the extracellular fluid volume of the calf. Using a measurement of the calf's circumference (), a resistivity value is calculated, normalized by the individual's body mass index (BMI), and then offset by a reference value to obtain a new variable, ΔnRho, which is shown, by comparison with a “gold standard” (FIGS. -), to be highly effective in predicting/estimating dry weight (FIGS. - and -). The techniques are easy to use and provide accurate dry weight predictions/estimations without substantially adding to the complexity or cost of dialysis procedures. The techniques can also be used for individuals who are not renal patients, e.g., patients suffering from other diseases in which fluid overload can occur, athletes, fitness enthusiasts, and the like.

8257280, Sep 4, 2012

May 13, 2011

13/107246

Nathan W. Levin - New York NY, US
Fansan Zhu - Flushing NY, US

Renal Research Institute, LLC - New York NY

A61B 5/103, A61B 5/117, A61B 5/05

600587, 600547

Methods and apparatus for providing bioimpedance analysis are provided. In certain aspects, equivalent circuit frequency response models are provided which lead to improved correlations with MRI data. The frequency response models take account of body composition, including the fat component of a body segment. Data obtained by performing bioimpedance spectroscopy (BIS) and MRI on the calves of subjects illustrates the improved correlations achieved compared to single frequency analyses at 50 kilohertz and analyses performed using the conventional Cole-Cole model.

5480565, Jan 2, 1996

Oct 8, 1993

8/134098

Nathan Levin - New York NY
Hans-Dietrich Polaschegg - D 61440 Oberursel, DE

B01D 6502, B01D 6506, A61L 216

210764

A method for reprocessing dialyzer cartridges used with kidney dialysis machines is provided. The method involves filling the blood and dialysate compartments of the dialyzer with an aqueous solution containing citric acid at a concentration of 1. 0-5. 0 wt. %, e. g. , 1. 5 wt. %, and then subjecting the dialyzer to an elevated temperature above 90. degree. C. and below 100. degree. C. , e. g. , 95. degree. C. , for a period of at least 15 hours, e. g. , 20 hours. Although citric acid is non-toxic and the temperature used is below the boiling point of water, the process has been found to produce a fully sterilized dialyzer. After reprocessing, the aqueous citric acid solution is preferably left in the dialyzer where it acts as a bacteriostatic agent during storage. Essentially no damage to the dialyzer and, in particular, to its semipermeable membrane results from either the reprocessing or storage procedures.

8419943, Apr 16, 2013

Jun 12, 2012

13/494506

Peter Kotanko - New York NY, US
Nathan W. Levin - New York NY, US

Fresenius Medical Care Holdings, Inc. - Waltham MA

B01D 59/30, B01D 59/32, B01D 61/14, B01D 61/24, A61M 1/14

210638, 210660, 604 401, 604 501

The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.